L. Kerrie

1.5k total citations · 1 hit paper
26 papers, 1.1k citations indexed

About

L. Kerrie is a scholar working on Genetics, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, L. Kerrie has authored 26 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 10 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in L. Kerrie's work include Chronic Lymphocytic Leukemia Research (12 papers), Advanced Breast Cancer Therapies (10 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). L. Kerrie is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Advanced Breast Cancer Therapies (10 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). L. Kerrie collaborates with scholars based in United States and Canada. L. Kerrie's co-authors include Wayne W. Hancock, Wei Gao, Vilmos Csizmadia, Jennifer King, Bao Lu, Ling Mai, Craig Gérard, Stephen T. Smiley, Norma P. Gerard and Brad S. Kahl and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

L. Kerrie

26 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection

2000 525 citations Wayne W. Hancock, Bao Lu et al. The Journal of Experimental Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L. Kerrie United States	12	548	509	320	236	204	26	1.1k
Teresa Owen United States	12	895 1.6×	262 0.5×	308 1.0×	187 0.8×	121 0.6×	14	1.5k
Friederike Kreisel United States	18	362 0.7×	384 0.8×	337 1.1×	206 0.9×	363 1.8×	61	1.4k
Mark W. Brunvand United States	15	554 1.0×	293 0.6×	375 1.2×	112 0.5×	176 0.9×	22	1.2k
Janet Ayello United States	21	529 1.0×	705 1.4×	368 1.1×	167 0.7×	214 1.0×	117	1.3k
Florian Eitelbach Germany	7	525 1.0×	325 0.6×	196 0.6×	97 0.4×	338 1.7×	9	1.1k
Hélder Trindade Portugal	17	421 0.8×	161 0.3×	353 1.1×	227 1.0×	53 0.3×	42	985
Peter Gribling United States	12	595 1.1×	174 0.3×	215 0.7×	132 0.6×	84 0.4×	12	1.0k
GJ Freeman United States	12	1.1k 2.0×	602 1.2×	220 0.7×	220 0.9×	286 1.4×	15	1.6k
Brandy Perkins United States	13	440 0.8×	369 0.7×	578 1.8×	119 0.5×	141 0.7×	18	1.4k
Rédouane Rouas Belgium	16	562 1.0×	195 0.4×	577 1.8×	266 1.1×	46 0.2×	26	1.3k

Countries citing papers authored by L. Kerrie

Since Specialization

Citations

This map shows the geographic impact of L. Kerrie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Kerrie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Kerrie more than expected).

Fields of papers citing papers by L. Kerrie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Kerrie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Kerrie. The network helps show where L. Kerrie may publish in the future.

Co-authorship network of co-authors of L. Kerrie

This figure shows the co-authorship network connecting the top 25 collaborators of L. Kerrie. A scholar is included among the top collaborators of L. Kerrie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Kerrie. L. Kerrie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

House, Nealia C., Maxine Chen, Liang Yuan, et al.. (2025). Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1 -Aberrant Ovarian and Endometrial Tumors. Cancer Research. 85(7). 1297–1309. 6 indexed citations

2.

House, Nealia C., Maxine Chen, Sima Khazaei, et al.. (2025). CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. npj Breast Cancer. 11(1). 135–135. 1 indexed citations

3.

Luo, Linjie, Juliana Navarro-Yepes, Tuyen Bui, et al.. (2024). Abstract PO1-18-05: Combination treatment with CDK2 inhibitor (BLU-222) and either palbociclib or ribociclib is synergistic in pre-clinical models of CDK4/6 inhibitor-resistant breast cancer. Cancer Research. 84(9_Supplement). PO1–18. 1 indexed citations

4.

House, Nealia C., Yuan Liang, Stephanie J. Lee, et al.. (2024). Abstract 1959: BLU-222, a potent and highly selective CDK2 inhibitor, demonstrates antitumor activity as monotherapy and as combination treatment in CCNE1-aberrant endometrial cancer models. Cancer Research. 84(6_Supplement). 1959–1959. 1 indexed citations

5.

House, Nealia C., Karen J. Ho, Hsin‐Jung Wu, et al.. (2023). Abstract P6-10-07: CDK2 inhibition with BLU-222 in combination with ribociclib demonstrates robust antitumor activity in pre-clinical models of CDK4/6 inhibitor-naïve and -resistant HR+/HER2- breast cancer. Cancer Research. 83(5_Supplement). P6–10. 8 indexed citations

6.

Kerrie, L., Kerry White, Jennifer Proctor, et al.. (2018). The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies. PLoS ONE. 13(8). e0200725–e0200725. 23 indexed citations

7.

O’Brien, Susan, Manish R. Patel, Brad S. Kahl, et al.. (2018). Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. American Journal of Hematology. 93(11). 1318–1326. 48 indexed citations

8.

White, Kerry, L. Kerrie, Jennifer Proctor, et al.. (2016). Abstract 376: Combination of duvelisib with either ibrutinib or dexamethasone prevents mTOR-dependent feedback in aggressive B-cell lymphoma cell lines. Cancer Research. 76(14_Supplement). 376–376. 5 indexed citations

9.

Patel, Manish R., Susan O’Brien, L. Kerrie, et al.. (2015). Early clinical activity and pharmacodynamic effects of duvelisib, a PI3K-δ,γ inhibitor, in patients with treatment-naïve CLL.. Journal of Clinical Oncology. 33(15_suppl). 7074–7074. 9 indexed citations

10.

Kerrie, L., David A. Winkler, Erin Brophy, et al.. (2014). Duvelisib (IPI-145) Inhibits Malignant B-Cell Proliferation and Disrupts Signaling from the Tumor Microenvironment through Mechanisms That Are Dependent on PI3K-δ and PI3K-γ. Blood. 124(21). 328–328. 17 indexed citations

11.

Flinn, Ian W., Manish R. Patel, Brad S. Kahl, et al.. (2013). Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia. Blood. 122(21). 677–677. 26 indexed citations

12.

Jimeno, Antonio, Glen J. Weiss, Wilson H. Miller, et al.. (2013). Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors. Clinical Cancer Research. 19(10). 2766–2774. 143 indexed citations

13.

Balakrishnan, Kumudha, Min Fu, Nathalie Y. Rosin, et al.. (2013). Inhibition Of PI3K-δ and -γ Isoforms By IPI-145 In Chronic Lymphocytic Leukemia Overcomes Signals From PI3K/AKT/S6 Pathway and Promotes Apoptosis. Blood. 122(21). 4167–4167. 3 indexed citations

14.

Rudin, Charles M., Antonio Jimeno, William H. Miller, et al.. (2011). A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3014–3014. 20 indexed citations

15.

Mandley, Everton, Kerry White, L. Kerrie, et al.. (2010). Abstract 5045: The Hh inhibitor IPI-926 inhibits relapse of a non-small cell lung cancer xenograft model following treatment with an EGF-R targeted tyrosine kinase inhibitor. Cancer Research. 70(8_Supplement). 5045–5045. 1 indexed citations

16.

Kerrie, L., Everton Mandley, Christine Pien, et al.. (2008). Depilation induced anagen as a model to study hedgehog pathway antagonist IPI-926: Implications for biomarker development. Cancer Research. 68. 2827–2827. 1 indexed citations

17.

Haskell, Christopher A., Wayne W. Hancock, David J. Salant, et al.. (2001). Targeted deletion of CX3CR1 reveals a role for fractalkine in cardiac allograft rejection. Journal of Clinical Investigation. 108(5). 679–688. 137 indexed citations

18.

Haskell, Christopher A., Wayne W. Hancock, David J. Salant, et al.. (2001). Targeted deletion of CX3CR1 reveals a role for fractalkine in cardiac allograft rejection. Journal of Clinical Investigation. 108(5). 679–688. 12 indexed citations

19.

Hancock, Wayne W., Bao Lu, Wei Gao, et al.. (2000). Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection. The Journal of Experimental Medicine. 192(10). 1515–1520. 525 indexed citations breakdown →

20.

Gao, Wei, L. Kerrie, Jennifer King, Stephen T. Smiley, & Wayne W. Hancock. (2000). TARGETING OF CHEMOKINE RECEPTORS CCR2 AND CCR5 PROLONGS MURINE CARDIAC ALLOGRAFT SURVIVAL.. Transplantation. 69(Supplement). S125–S125. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact